GERON CORP Nontrade Receivables, Current
GERON CORP (GERN) had Nontrade Receivables, Current of $1.86 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:NontradeReceivablesCurrent · last filed 2026-08-05
- 2026-06-30: Nontrade Receivables, Current $1.86M.
- 2026-03-31: Nontrade Receivables, Current $2.21M.
- 2025-12-31: Nontrade Receivables, Current $2.24M.
- 2025-09-30: Nontrade Receivables, Current $2.29M.
| Period end | Nontrade Receivables, Current |
|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.24M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $2.29M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $2.75M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.82M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.85M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.08M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.25M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.63M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.66M 10-K · filed 2025-02-27 |
| 2023-09-30 | $14.75M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.19M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.60M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.14M 10-K · filed 2024-02-28 |
| 2022-09-30 | $22.22M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $4.25M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $5.24M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.76M 10-K · filed 2023-03-16 |
| 2021-09-30 | $610.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $714.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $759.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $722.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $989.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $822.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $701.00K 10-Q · filed 2020-05-28 |
| 2019-12-31 | $802.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $795.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $838.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $976.00K 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.17M 10-K · filed 2020-03-12 |
| 2018-09-30 | $778.00K 10-Q · filed 2018-11-01 |
| 2018-06-30 | $773.00K 10-Q · filed 2018-07-31 |
| 2018-03-31 | $569.00K 10-Q · filed 2018-05-10 |
| 2018-01-01 | $640.00K 10-K · filed 2019-03-07 |
| 2017-12-31 | $436.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $514.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | $457.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $597.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $475.00K 10-K · filed 2018-03-16 |
| 2016-06-30 | $586.00K 10-Q · filed 2016-08-03 |
| 2016-03-31 | $624.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.21M 10-K · filed 2017-03-01 |
| 2015-09-30 | $1.24M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $1.50M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $1.19M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $963.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | $787.00K 10-Q · filed 2014-11-05 |
| 2014-06-30 | $1.26M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $1.44M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $564.00K 10-K · filed 2015-03-11 |
| 2013-09-30 | $555.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $480.00K 10-Q · filed 2013-08-08 |
| 2013-03-31 | $921.00K 10-Q · filed 2013-05-03 |
| 2012-12-31 | $752.00K 10-K · filed 2014-03-17 |
| 2012-09-30 | $842.00K 10-Q · filed 2012-11-02 |
| 2012-06-30 | $932.00K 10-Q · filed 2012-08-03 |
| 2012-03-31 | $866.00K 10-Q · filed 2012-05-07 |
| 2011-12-31 | $1.40M 10-K · filed 2013-03-15 |
| 2011-09-30 | $1.57M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $1.63M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $1.80M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |